Effects of Vitamin D Supplementation on Exacerbation in Patients with Severe COPD
Journal
MedPress Public Health and Epidemiolog
Date Issued
2022-07-12
Author(s)
Petrova, Tatjana
Kamchevska Kochovska, Nade
Bislimovska, Dragana
DOI
10.33582/mpphe.2022.202206002
Abstract
Introduction: Results from several studies indicated that vitamin D plays a role in a variety
of immunologic processes such as modulation of inflammatory pathways and susceptibility to
infections.
Aim of the study: To assess the effects of vitamin D supplementation on bacterial
exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) with low
vitamin D serum level.
Methods: We performed an observational, non-randomized, open-label study including 36
patients with severe COPD who besides the recommended chronic treatment for stable disease
took oral vitamin D supplementation in dose of 2000 IU daily during a six month-period (Group
1). In addition, 35 patients with severe COPD, matched to the study subjects of the Group 1 by
sex, age and serum vitamin D level, who did not receive vitamin D supplementation served as
controls (Group 2). Analysis of exacerbations, including their incidence and duration, as well
as incidence of relapses and duration of exacerbation-free interval, was done for each study
subjects based on daily diary cards maintained by all of them during the mentioned period.
Results: Mean serum vitamin D levels at baseline did not differ significantly between
examined groups (21.7 vs. 22.1; P = 0.457). At the end of the study its mean level was
significantly higher in the Group 1 as compared to Group 2 (30.1 vs. 23.4; P = 0.000). Mean
number of the first exacerbation over a six month-period was significantly lower in the Group
1 as compared to their mean number in the Group 2 (0.8 vs. 0.9; P = 0.001). Mean duration of
the first exacerbation in the Group 1 (6.7 ± 1.2 days) was significantly lower as compared to its
mean duration in the Group 2 (7.2 ± 1.3 days) (P = 0.033). Mean number of relapses registered
in the Group 1 (0.2 ± 0.1) was significantly lower than its mean number registered in the Group
2 (0.4 ± 0.2) (P = 0.000). Mean exacerbation-free interval in the Group 1 (39.3 ± 10.1 days) was
significantly longer than in the Group 2 (33.7 ± 11.8 days) (P = 0.052).
Conclusion: Our findings indicated that vitamin D supplementation may impact the
incidence and duration of bacterial exacerbations in patients with COPD. There is a need of
further studies to elucidate the role of vitamin D supplementation on the course of COPD.
of immunologic processes such as modulation of inflammatory pathways and susceptibility to
infections.
Aim of the study: To assess the effects of vitamin D supplementation on bacterial
exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) with low
vitamin D serum level.
Methods: We performed an observational, non-randomized, open-label study including 36
patients with severe COPD who besides the recommended chronic treatment for stable disease
took oral vitamin D supplementation in dose of 2000 IU daily during a six month-period (Group
1). In addition, 35 patients with severe COPD, matched to the study subjects of the Group 1 by
sex, age and serum vitamin D level, who did not receive vitamin D supplementation served as
controls (Group 2). Analysis of exacerbations, including their incidence and duration, as well
as incidence of relapses and duration of exacerbation-free interval, was done for each study
subjects based on daily diary cards maintained by all of them during the mentioned period.
Results: Mean serum vitamin D levels at baseline did not differ significantly between
examined groups (21.7 vs. 22.1; P = 0.457). At the end of the study its mean level was
significantly higher in the Group 1 as compared to Group 2 (30.1 vs. 23.4; P = 0.000). Mean
number of the first exacerbation over a six month-period was significantly lower in the Group
1 as compared to their mean number in the Group 2 (0.8 vs. 0.9; P = 0.001). Mean duration of
the first exacerbation in the Group 1 (6.7 ± 1.2 days) was significantly lower as compared to its
mean duration in the Group 2 (7.2 ± 1.3 days) (P = 0.033). Mean number of relapses registered
in the Group 1 (0.2 ± 0.1) was significantly lower than its mean number registered in the Group
2 (0.4 ± 0.2) (P = 0.000). Mean exacerbation-free interval in the Group 1 (39.3 ± 10.1 days) was
significantly longer than in the Group 2 (33.7 ± 11.8 days) (P = 0.052).
Conclusion: Our findings indicated that vitamin D supplementation may impact the
incidence and duration of bacterial exacerbations in patients with COPD. There is a need of
further studies to elucidate the role of vitamin D supplementation on the course of COPD.
File(s)![Thumbnail Image]()
Loading...
Name
Effects of Vitamin D Supplementation on Exacerbation in Patients with Severe COPD.pdf
Size
542.41 KB
Format
Adobe PDF
Checksum
(MD5):3b9d4252d7ec605940c35e1b94c909a5